Pharmacology
GLP1
+2
Jun 16, 2026
•
9 min read
Glucagon Doesn't Win the Scale. It Wins the Liver.
Survodutide and pemvidutide keep landing below 20% on body weight — while clearing liver fat at rates no pure GLP-1 can touch. A dispatch on the ADA 2026 readouts, and the case for grading incretins on the right organ.
GLP1
+1
Jun 6, 2026
•
7 min read
GLP-1 Resistance Is Real. You Probably Don’t Have It.
A genetic study just caught true GLP-1 resistance in the act. Almost no one being called a “non-responder” fits the description.
GLP1
+1
May 23, 2026
•
9 min read
The Accidental Hormone.
A century-long hunt for a phantom gut hormone, a peptide chemist written out of the story, and a venomous desert lizard. Here is where Ozempic actually comes from — and who actually found it.
GLP1
+2
May 19, 2026
•
13 min read
ECO 2026: The Maintenance Era Begins.
Istanbul gave us the answers we have been waiting for. Obesity is now being treated like every other chronic disease — and the data is on the right side of history.
CV
+3
Apr 15, 2026
•
16 min read
Statins Don't Cause What You Think They Cause. Except When They Do.
Muscle damage. Memory loss. Cancer. Diabetes. Four fears, one physician, and what the evidence actually shows.
GLP1
+3
Mar 27, 2026
•
15 min read
What Semaglutide Teaches Us About How GLP-1 Regulates Body Weight
It's not the injection site. It's not gut GLP-1. It's not thermogenesis. The pharmacokinetics of semaglutide across multiple trials offer a surprisingly clean window into how this molecule — and this biology — actually works.
